Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 7/20 | 0.35 |
| ▸ | BUB1 | O43683 | 1/20 | 0.35 |
| ▸ | NAMPT | P43490 | 5/20 | 0.34 |
| ▸ | PIM1 | P11309 | 1/20 | 0.33 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.33 |
| ▸ | UCHL1 | P09936 | 2/20 | 0.32 |
| ▸ | BRD4 | O60885 | 1/20 | 0.32 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6794985 | 0.80 | SIGMAR1 (0.32) | BUB1 | |
| SCHEMBL6793213 | 0.78 | SIGMAR1 (0.35) | CYP11B2 | |
| SCHEMBL6798659 | 0.76 | SIGMAR1 (0.36) | BUB1 | |
| SCHEMBL4260846 | 0.73 | SIGMAR1 (0.36) | — | |
| Hydrochloric Acid SCHEMBL4263968 | 0.72 | PDPK1 (0.33) | NAMPTCYP11B2 | |
| SCHEMBL29814515 | 0.71 | PIK3CA (0.42) | GPR119BUB1NAMPT | |
| SCHEMBL6794720 | 0.71 | BRAF (0.34) | — | |
| SCHEMBL6794726 | 0.71 | BRAF (0.34) | — | |
| SCHEMBL460089 | 0.70 | CDC7 (0.39) | — | |
| Hydrochloric Acid SCHEMBL6798947 | 0.69 | GRIN2B (0.34) | NAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040127492-A1 | Cyclic pyrazoles for the inhibition of mitogen activated protein kinase-activated protein kinase-2 | PHARMACIA CORPORATION | 2004-07-01 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127492-A1 | Cyclic pyrazoles for the inhibition of mitogen activated protein kinase-activated protein kinase-2 | MKNK2, MAPKAPK2, MAP3K2 | GPR119 1076/4885BUB1 283/4885NAMPT 658/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.